Citizens Business Bank Acquires Shares of 1,790 Medpace Holdings, Inc. $MEDP

Citizens Business Bank bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 1,790 shares of the company’s stock, valued at approximately $920,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in MEDP. Intech Investment Management LLC increased its stake in Medpace by 31.9% during the 3rd quarter. Intech Investment Management LLC now owns 18,395 shares of the company’s stock worth $9,458,000 after acquiring an additional 4,448 shares during the period. Empirical Asset Management LLC lifted its position in shares of Medpace by 9.8% during the 3rd quarter. Empirical Asset Management LLC now owns 2,189 shares of the company’s stock valued at $1,125,000 after acquiring an additional 196 shares during the period. Waddell & Associates LLC acquired a new stake in shares of Medpace during the 3rd quarter worth $460,000. Optiver Holding B.V. bought a new position in shares of Medpace in the third quarter worth $27,000. Finally, Compound Planning Inc. raised its stake in Medpace by 10.9% in the third quarter. Compound Planning Inc. now owns 1,303 shares of the company’s stock valued at $670,000 after purchasing an additional 128 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on MEDP. Truist Financial decreased their target price on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Leerink Partners cut their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Four investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $483.45.

Insider Activity at Medpace

In other news, CEO August J. Troendle sold 668 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total transaction of $394,580.92. Following the sale, the chief executive officer directly owned 646,184 shares in the company, valued at approximately $381,694,426.96. The trade was a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold 38,997 shares of company stock worth $23,136,442 over the last quarter. Company insiders own 20.30% of the company’s stock.

Medpace Price Performance

Shares of Medpace stock opened at $438.08 on Thursday. The company’s 50 day moving average price is $549.02 and its two-hundred day moving average price is $538.89. The firm has a market capitalization of $12.43 billion, a P/E ratio of 28.63, a P/E/G ratio of 2.12 and a beta of 1.42. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.Medpace’s revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the company earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.